From this May 16, 2006 article at CNNMoney.com - which shows that Merck was counting heavily on Gardasil to save the day, financially speaking, in the wake of the Vioxx withdrawal and expiring patents on some of its most profitable drugs.
Noteworthy content:
Merck needs a hit, and it just might be on the verge of getting one, thanks to some delicate footwork with the religious right.
and this:
If approved Gardasil could be a multi-billion blockbuster for Merck.
and this:
The experimental vaccine is backed by strong clinical data and has been hailed as a bright light for Merck (up $0.60 to $35.29, Research), a drug giant that is losing billions of dollars in annual sales to impending patent expirations, as well as the withdrawal of its blockbuster Vioxx.
and finally this:
If the FDA approves Gardasil, it would help fill part of the sales vacuum left by Vioxx, an arthritis painkiller that Merck pulled off the market in 2004 after a study showed an increased the risk of heart attacks and strokes. Not only did this erase $2.5 billion in annual sales, but about 11,500 lawsuits have been filed against Merck by former patients and their families.
1 comments:
I am here in Vancouver British Columbia Canada reading all this information about Gardasil.The uninformed Provincial government are trying to push this up here as well.They want to inject my daughter next year. Not if i can help it.
Post a Comment